Newer therapies - DiabetesontheNet

Real-world experience of SGLT2 inhibitors: A useful addition to the arsenal of antidiabetes medication. An Irish perspective

Putting type 2 diabetes into remission: Moving towards non-surgical interventions in the future

Glucagon-like peptide-1 receptor agonists: A better option for treating and preventing steatohepatitis?

EMPA-REG Renal: Are we there yet?

A new age in management of type 2 diabetes treatment

Keeping abreast of the latest diabetes research: Glycaemic control, hypoglycaemia, combination therapy and inpatient care

Experience of and predictors of response to dapagliflozin in a real-life cohort of people with type 2 diabetes

Evaluation of a combination of SGLT2 inhibitor and GLP-1 receptor agonist treatment in type 2 diabetes

Keeping abreast of the latest diabetes research: Impact of diabetes, hypoglycaemia awareness and GLP-1 analogues

Recent PCDS activities

Diabetes and bone health

Very-low-energy diets: A useful tool in type 2 diabetes management?

Top-line data show cardiovascular benefit with liraglutide

Keeping abreast of the latest diabetes research: HbA1c screening, older people and empagliflozin

51st Annual Meeting of the European Association for the Study of Diabetes

Unit 1 – Core aspects of care: Hyperglycaemia in type 2 diabetes: Newer blood glucose-lowering therapies

Pharmacotherapies to manage diabesity: An update

Differentiating between GLP-1 receptor agonists and DPP-4 inhibitors